I told my friend: Neither option is inherently good or bad. Its more about what youre comfortable with
Because it targets GLP-1, GIP, and glucagon pathways, side effects and monitoring needs may be more complex than single-pathway medications
Thus, immunoneutralization with antibodies against GIP significantly inhibited oral-glucose-stimulated insulin secretion ( The interest now focussed on gut glucagon (36), was in effect a C-terminally extended form of glucagon
Who should not take GLP-1s GLP-1s in all forms are unsuitable for people who: are pregnant or breastfeeding do not meet the eligibility criteria have a family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2) Medical Perspective Patients with needle phobia, a preference for pill-based routines, or good adherence to oral administration guidelines may be better suited to oral GLP-1 formulations like semaglutide (Rybelsus, Wegovy), which can enhance treatment acceptance and potentially offer strong glycemic or weight control
2015;10(6):e0131122
Orforglipron (Foundayo) is a daily tablet that works on the GLP-1 pathway to reduce appetite, while Mounjaro is a weekly injection that targets both GLP-1 and GIP, making it more potent
